stockrowUnited Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) Revenue
United Therapeutics Corporation's revenue for fiscal 2025 was $3.2B, up 10.6% from $2.9B in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.2B. Over the past ten years it has ranged from $1.4B (fiscal 2019) to $3.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 6 consecutive fiscal years. United Therapeutics Corporation ranks 12th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.2B | 10.61% |
| FY2024 | $2.9B | 23.63% |
| FY2023 | $2.3B | 20.20% |
| FY2022 | $1.9B | 14.88% |
| FY2021 | $1.7B | 13.63% |
| FY2020 | $1.5B | 2.38% |
| FY2019 | $1.4B | (11.00%) |
| FY2018 | $1.6B | (5.65%) |
| FY2017 | $1.7B | 7.91% |
| FY2016 | $1.6B | 9.07% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $832.5M | 6.28% |
| Jun 2026 | $783.3M | 0.23% |
| Mar 2026 | $781.5M | (1.10%) |
| Dec 2025 | $790.2M | (1.16%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $30.0B |
| HLN Haleon PLC Sponsored ADR compare | $18.1B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $17.2B |
| VTRS Viatris Inc. compare | $14.7B |
| ZTS Zoetis Inc. compare | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| UTHR United Therapeutics Corporation | $3.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on UTHR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement